Meta-analysis of Clinical Efficacy and Safety of Pertuzumab and Trastuzumab Combined Therapy in HER-2 Positive Breast Cancer

• DOI: 10.53964/jmmo.2023004
• Publication Date: 2023-05-06T03:24:53Z
• Authors: Xiaoyu Zhang; Hui Zhang; ; Hengle Zhang; ; Yulai Yin; ; Yue Ren; ; Xiaoning Kang; ; Lijun Jin; ; Jie Bai
• Keywords: Pertuzumab

Objective: To systematically evaluate the clinical efficacy and safety of pertuzumab trastuzumab combined therapy in human epidermal growth factor receptor 2 (HER-2) positive breast cancer through a meta-analysis. Methods: English databases including PubMed, Embase, Cochrane Central Register Controlled Trials, as well Chinese China National Knowledge Infrastructure, Wanfang Database, Biomedical Literature Service System (Sinomed), were searched for randomized controlled trials (RCTs) comparing (experimental group) with alone (control treatment HER-2 cancer. The literature search time was from establishment database to July 2022. Two reviewers independently screened literature, extracted data, assessed quality literature. Meta-analysis performed using Review Manager 5.4 software. Results: A total 9 RCTs involving 7199 patients included results effectiveness indicators showed that risk tumor progression receiving dual-targeted significantly lower than [Hazard ratios (HR) = 0.68, 95% confidence intervals (CI) (0.58, 0.79), P<0.00001]; overall survival (OS) longer [HR=0.73, CI (0.59, 0.88), P<0.0009]. In terms safety, there no statistical difference incidence severe adverse events ≥3 grade neutropenia between experimental control groups (P>0.05), but diarrhea group higher [relative risks 2.44, (1.95, 2.99), P<0.00001]. Conclusion: has significant patients, its application can further improve patients' progression-free OS. However, it also increases reactions certain extent. Therefore, practice, is necessary strengthen monitoring protection relevant patients.